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Macular Choroidal Thickness in AS. Ellabban AA, et al. 
Abstract 
 
PURPOSE: To study the mean choroidal thickness and volume of the macula in eyes 
with angioid streaks using swept source optical coherence tomography (OCT) in the 
1,050 nm wavelength range. 
DESIGN: Prospective case series. 
METHODS: The macular area of 39 eyes of 23 patients with angioid streaks and of 20 
normal eyes of 20 matched controls (Group 1) was studied with a swept source OCT 
prototype system. Eyes with angioid streaks were classified into one of four groups: 
those without choroidal neovascularization (CNV) (Group 2); those with CNV that had no 
history of treatment (Group 3); those with CNV that had previously received only 
anti-vascular endothelial growth factor treatments (Group 4); and those with CNV that 
had previously received photodynamic therapy (Group 5). Using a raster scan protocol 
with 512 × 128 A-scans, we produced a macular choroidal thickness map (6 × 6 mm2). 
RESULTS: There were no significant differences in age, axial length, or refractive error 
among the five groups. Mean choroidal thickness of the macula in Group 2 (218.9 ± 46.8 
µm) was as great as was that in Group 1 (218.8 ± 69.2 µm). However, the macular 
choroidal thickness in Group 3 (119.7 ± 49.2 µm), Group 4 (140.1 ± 64.9 µm), and Group 
5 (144.0 ± 52.6 µm) was significantly less than that of Group 1 (P < .05). There were no 
statistical differences between Groups 3-5. In each group, the choroid of the nasal 
quadrant was significantly thinner compared to that in other quadrants (P < .05). 
CONCLUSIONS: The choroid in eyes with angioid streaks without CNV was as thick as 
was that in normal controls, but was significantly thinner in eyes with angioid streaks that 
had developed CNV. 
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Pseudoxanthoma elasticum is a rare multisystem disorder associated with a mutation in 
the ABCC6 gene.1 Pseudoxanthoma elasticum causes progressive fragmentation and 
calcification of elastic fibers in connective tissue, resulting in pathologic changes that are 
most pronounced in the dermis, blood vessels, and Bruch’s membrane.2 Characteristic 
fundus changes of pseudoxanthoma elasticum are peau d’orange, areas of chorioretinal 
atrophy, and angioid streaks.3, 4 Angioid streaks are irregular crack-like dehiscences in 
Bruch’s membrane which often allow the ingrowth of choroidal neovascularization (CNV) 
through Bruch’s membrane defects.3, 4 CNV secondary to angioid streaks occurs in 
72–86% of eyes, is bilateral in more than 70% of cases, and often occurs at a younger 
age than does the CNV of age-related macular degeneration (AMD). Because CNV 
secondary to angioid streaks is often refractory to treatment, it leads in many cases to 
poor vision if the CNV involves the macular area.5-9 
     Recently, the choroid, which is a structure with one of the highest blood flows in the 
body,10 is reported to be involved in the pathogenesis of various ocular diseases, 
including AMD,11 polypoidal choroidal vasculopathy,12 central serous chorioretinopathy,13 
Vogt-Koyanagi-Harada disease,14 and myopic chorioretinal degeneration.15 In angioid 
streaks, although Bruch’s membrane is thought to be most affected, previous reports 
have suggested that the choroid is also involved in the pathogenesis of CNV.3, 4 Today, 
optical coherence tomography (OCT) is used to measure retinal thickness and to detect 
morphologic changes in various retinal diseases. However, commercially available OCT 
equipment visualizes the entire choroid only in eyes with high myopia because of low 
penetration and high backscattering at the level of the retinal pigment epithelium (RPE).16, 
17 So, to date, little in vivo information is available on the choroidal changes associated 
with angioid streaks. 
     Since Spaide and associates16 introduced enhanced depth imaging OCT based on 
spectral-domain OCT technology, many investigators have studied the choroidal 
thickness in eyes with various pathologies.11, 14, 15, 18-25 Although normal choroidal 
thickness in the macula varies with region and can vary even more in pathologic 
conditions, in most of these studies the choroidal thickness was measured at the foveal 
center or, sometimes, at several measurement points.11, 14, 15, 18-25 This is because 
enhanced depth imaging requires the averaging of 50-100 B-scans of an identical 
location of interest,16 hindering us from high density scanning. With the advances in OCT 
technology, the recent generation has utilized swept source laser technology, which has 
the advantage of a high speed scanning rate and low sensitivity roll-off versus depth 
compared to spectral-domain OCT.26-34 With the use of a light source at 1 μm wavelength 
region, swept source OCT allows for a high contrast, high-penetration image of the entire 


































































Macular Choroidal Thickness in AS. Ellabban AA, et al. Page 3 
us to obtain a three-dimensional (3D) high contrast image of the choroid. 
     In the study described herein, we scanned the macular area of eyes with angioid 
streaks associated with pseudoxanthoma elasticum using swept source OCT at 1,050 
nm with a 3D raster scan protocol, and produced a choroidal thickness map of the 
macular area. By applying the grid used by the Early Treatment Diabetic Retinopathy 
Study (ETDRS) to this map, the mean choroidal thickness and volume in each sector 
was measured and compared with those of normal subjects. 
 
PATIENTS AND METHODS 
 
This prospective study consisted of 39 eyes of 23 patients with angioid streaks 
secondary to pseudoxanthoma elasticum. The macular area of these 39 eyes was 
examined with a swept source OCT prototype system at Kyoto University Hospital 
between September 2010 and November 2011. The diagnosis of pseudoxanthoma 
elasticum was based on systemic manifestations, fundus examination, and fluorescein 
angiography,35 and the diagnosis was confirmed by characteristic histopathologic 
abnormalities in a skin biopsy. 
     All subjects underwent a thorough ocular examination, including autorefractometry 
(ARK1; Nidek, Gamagori, Japan), best-corrected visual acuity measurement with a 
5-meter Landolt chart, axial length measurement using ocular biometry (IOLMaster; Carl 
Zeiss Meditec, Jena, Germany), slit lamp examination, intraocular pressure 
measurement, dilated color fundus photography (TRC50LX; Topcon Corp., Tokyo, 
Japan), and prototype swept source OCT examination. All eyes with angioid streaks 
underwent simultaneous fluorescein angiography and indocyanine green angiography 
using Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, Germany). Eyes with 
poor images due to opaque media (e.g., cataracts or vitreous hemorrhage) or to unstable 
fixation were excluded from the study. 
     Eligible eyes with angioid streaks were classified into four groups based on the 
presence of CNV and the previous treatment of the CNV: eyes with angioid streaks 
without CNV (Group 2), eyes with CNV secondary to angioid streaks that had no history 
of treatments (Group 3), eyes with CNV secondary to angioid streaks that had previously 
received only anti-vascular endothelial growth factor (VEGF) treatments with no history of 
photodynamic therapy (PDT) (Group 4), and eyes with CNV secondary to angioid streaks 
that did have a history of PDT (Group 5). Data obtained from the four groups with angioid 
streaks were compared with data obtained from 20 healthy eyes (20 subjects) of controls, 
matched for age, axial length and refractive error (Group 1).36 Exclusion criteria for these 
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including AMD, diabetic retinopathy, central serous chorioretinopathy, epiretinal 
membrane, and macular dystrophy, or a history of intraocular surgery. Subjects with 
systemic diseases or conditions that might affect retinal or choroidal thickness were also 
excluded. 
 
SWEPT SOURCE OCT SYSTEM AND SCAN PROTOCOLS 
The prototype swept source OCT system (Topcon Corp.) used in the current study has 
been reported previously.36 In brief, this swept source OCT system utilizes a light source 
of a wavelength-sweeping laser centered at 1,050 nm with 100,000 Hz repetition rate.  
Axial and transverse resolutions were 8 µm and 20 µm in tissue, respectively. Swept 
source OCT imaging operated at 1 μm wavelength region was conducted at ~1 mW on 
the cornea, which is well below the safe retinal exposure limit established by the 
American National Standards Institute. 
     Swept source OCT examinations of the eligible subjects were performed by trained 
examiners after pupil dilation. A 3D imaging data set was acquired on each subject by 
using a raster scan protocol of 512 (horizontal) × 128 (vertical) A-scans per data set (total 
65,536 axial scans/data set) in 0.8 seconds. Each 3D raster scan covered a 6 × 6-mm2 
area centered on the fovea, which was confirmed by internal-fixation and by a fundus 
camera built into the swept source OCT system. To reduce speckle noise, each image 
was enhanced by weighted moving average of three consecutive original images. 
     In each subject, 50 averaged horizontal and vertical scan images in 12 mm 
transverse scan length were obtained as well. The 50 single images, where each image 
consisted of 1,024 A-scans, were registered and averaged by software to create an 
averaged single image. The vertical scan was centered on the fovea while the horizontal 
scan was centered on the midpoint between the fovea and optic disc. 
 
CHOROIDAL THICKNESS AND VOLUME MEASUREMENT PROTOCOL 
The choroidal thickness was measured as the distance between the outer border of the 
RPE and the chorioscleral border. In areas where the RPE was defective, the Bruch’s 
membrane was considered as an inner border of the choroid. In each image of the 
3D-data set, lines of both RPE and the chorioscleral border were determined manually by 
a trained observer in a masked fashion. Automated built-in calibration software 
determined the distance between these two lines. The measurement points per image 
consisted of 512 points with an interval of ~12 μm. From the 128 images of each 3D-data 
set, a choroidal thickness map of 6 × 6-mm2 area was created. After the choroidal 
thickness map was obtained, the ETDRS grid was applied to the map.37 
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grid between the five study groups and also compared these values within each group.  
Using the averaged OCT images, we also performed measurement of retinal thickness 
and of choroidal thickness at the center of the fovea. Retinal thickness was defined as 
the distance between the vitreoretinal interface and RPE. 
 
STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS statistical software (version 16; SPSS Inc., 
Chicago, Illinois). All values are presented as mean ± standard deviation. The data were 
analyzed using one-way analysis of variance with Tukey’s post-hoc analysis to compare 
mean choroidal thickness and volume at different regions. To compare the thickness and 
volume data in each group, two-way analysis of variance was used. P values less 




In the current study, 39 eyes (23 patients, 14 men and 9 women) with angioid streaks 
secondary to pseudoxanthoma elasticum, ranging in age from 57 to 80 years (mean: 
65.4 ± 7.4 years), were examined. Mean refractive error was -1.19 ± 2.15 diopters 
(range: -5.5 to +1.75 diopters). Mean axial length was 23.83 ± 1.39 mm (range: 22.15 to 
26.54 mm). Eyes with angioid streaks were classified into four groups: those with angioid 
streaks but with no CNV (Group 2, n = 6), eyes with CNV secondary to angioid streaks 
with no history of treatments for their CNV (Group 3, n = 7), eyes with CNV secondary to 
angioid streaks with a history of only anti-VEGF treatments for their CNV (Group 4, n = 
11), and eyes with CNV secondary to angioid streaks with a history of PDT (Group 5, n = 
15). Table 1 shows the ocular characteristics of each group. All eyes in Group 4 received 
anti-VEGF treatments for CNV, with the mean number of injections being 3.4 ± 2.1. Eyes 
in Group 5 received 2.9 ± 1.9 PDT treatments and 3.1 ± 3.9 anti-VEGF treatments.  




The swept source OCT system operated at 1,050 nm wavelength range enables 
visualization of the clear structure of the posterior pole as well as allowing deeper 
penetration into the choroid. Multi-averaged scans of 12 mm in length revealed structures 
of the retina and choroid, which allowed precise identification in all eyes of the 
chorioscleral border beyond the vascular arcade (left, Figure 1). Figure 2 shows typical 
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was well-preserved and was as thick as was that of healthy controls (Group 1).  
Multi-averaged scans of the current OCT system often show a layer of medium diameter 
blood vessels (Sattler's layer) and an outermost layer of the choroid consisting of larger 
diameter blood vessels (Haller's layer). However, the choroid in eyes with CNV 
secondary to angioid streaks was remarkably thin with disorganized configuration of 
choroidal vessels (Groups 3-5), regardless of a history of treatment. In eyes with CNV 
secondary to angioid streaks that had a history of PDT (Group 5), choroidal thickness 
was reduced not only in the macular area, where the PDT was performed, but also 
beyond the vascular arcade. 
  
MEAN CHOROIDAL THICKNESS AND VOLUME 
Using a raster scan protocol with 512 × 128 A scans, 3D imaging data of the 6 × 6-mm2 
area were acquired. By weighted moving average, each image had quality sufficient to 
allow delineation of both the outer border of the RPE and the chorioscleral border, even 
in eyes with retinal pathology (middle and right, Figure 1; Supplemental Videos 1 and 2).  
Based on 128 images of the 3D-data set, a choroidal thickness map of the 6 × 6-mm2 
area centered on the fovea was created for each eye. In the current study, the mean 
choroidal thickness in the macula (within the outer circle of the ETDRS grid) was 218.8 ± 
69.2 µm in Group 1, 218.9 ± 46.8 μm in Group 2, 119.7 ± 49.2 µm in Group 3, 140.1 ± 
64.9 µm in Group 4, and 144.0 ± 52.6 µm in Group 5. Mean macular choroidal thickness 
in Group 2 was as great as that in Group 1 (Figure 3). However, mean macular choroidal 
thickness in Groups 3-5 was significantly less than that in Group 1 (P < .05, respectively) 
(Figure 4). There were no statistical differences between Groups 3-5. 
 
CHOROIDAL VOLUME 
Macular choroidal volume (within the outer circle of the ETDRS grid) was 6.183 ± 1.957 
mm3 in Group 1, 6.185 ± 1.323 mm3 in Group 2, 3.381 ± 1.389 mm3 in Group 3, 3.959 ± 
1.853 mm3 in Group 4, and 4.070 ± 1.487 mm3 in Group 5. In Groups 3-5, choroidal 
volume of the macula was significantly reduced compared with that of Group 1 (P < .05, 
respectively). There were no statistical differences between Groups 3-5. Table 2 shows 
the choroidal volume in each sector of the ETDRS grid. In most sectors, choroidal 
volume in Groups 3-5 was significantly less than that of Group 1, respectively. 
 
REGIONAL CHOROIDAL THICKNESS 
Table 3 shows the mean choroidal thickness of each area of the ETDRS grid in the five 
groups. Mean choroidal thickness within the central area was 238.7 ± 75.0 µm in Group 1, 
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and 130.5 ± 52.8 μm in Group 5. However, in these choroidal thickness maps, there were 
regional irregularities in most eyes (Figures 3 and 4). In all groups, the choroid in the 
nasal quadrant was thinner than in other quadrants; the mean thickness of the outer 




Enhanced depth imaging OCT is coupled usually with multiple averaging in order to 
produce high contrast images with low speckle noise.16 In the studies that have utilized 
the enhanced depth imaging technique, it was difficult to provide as many sections as 
does 3D imaging and the choroidal thickness was measured only at the foveal center or, 
in some cases, at several measurement points.20, 21, 38-42 However, because the choroid 
often shows focal thickening or thinning, measurement at a single point may be 
influenced by such irregularity or even by focal indistinctness of the chorioscleral 
border.11, 18, 43 In the current study, the macular area of eyes with angioid streaks was 
examined with a raster scan protocol using a prototype swept source OCT, which 
operated at 1 μm wavelength region. Swept source OCT at this longer wavelength has 
higher penetration and lower scattering at the RPE, and thus allows for full-depth imaging 
of the choroid.36 The tunable laser source in the swept source OCT has a lower signal 
decay versus depth than does the existing spectral-domain OCT system. In addition, 
high-speed scanning coupled with the high sensitivity of the swept source OCT allowed 
us to obtain highly reproducible measurements of the choroidal thickness using a 3D 
raster scan protocol. Averaging of thickness values obtained at multiple measurement 
points in the 3D data set contributed to lessening of the error in determining choroidal 
thickness in the macular area.26, 36 
     In the current study, the choroid of eyes with angioid streaks without CNV was as 
thick as was that in normal controls. Multi-averaged scans of the current OCT system 
often show a layer of medium diameter blood vessels (Sattler's layer) and an outermost 
layer of the choroid consisting of larger diameter blood vessels (Haller's layer).34  
However, the choroid was significantly thinner in eyes with angioid streaks that had 
developed CNV. Because the configuration of choroidal vessels is disorganized, it is 
difficult to determine which layer was primarily degenerated. Furthermore, because this 
study was performed on a cross-sectional basis, the cause of this finding is uncertain, but 
several hypotheses can be proposed. 
     First, eyes with angioid streaks may show progressive thinning of the choroid over 
time. This thinning becomes most evident at a later stage of the disease, at which time 
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actually contribute to the development of CNV. It is possible that eyes with angioid 
streaks have a wide range of choroidal thicknesses, and that eyes with a thin choroid 
develop CNV, while eyes with a more preserved choroid rarely do. Previous 
histopathologic reports4, 44, 45 have shown that angioid streaks are accompanied by 
atrophic degeneration of the overlying RPE and by focal breaks or even an absence of 
the underlying choriocapillaris. These histopathologic changes, which might be due 
primarily to thickening of the choroidal capillary walls or, more probably, obliteration of 
their lumens, may be associated with development of CNV. Third, the atrophy of RPE 
and choriocapillaris that is often seen around the CNV may be associated with the 
macular choroidal thinning in eyes with CNV secondary to angioid streaks. 
     In the current study, the choroidal thinning was seen in eyes with CNV, independent 
of a history of treatments for CNV. However, it is possible that previous treatments for 
CNV are also involved in the choroidal thinning. Maruko and associates20, 42 reported 
recently that subfoveal choroidal thickness is decreased after PDT in eyes with 
polypoidal choroidal vasculopathy or central serous chorioretinopathy. However, it has 
also been reported that the subfoveal choroidal thickness is increased during the active 
phase of these diseases,11, 39 so it is possible that PDT does not make the choroid 
pathologically thin by its direct photoreactive effect on the choroidal vessels, but, rather, 
only reduces the increased subfoveal choroidal thickness to physiologic levels by the 
reduction of the choroidal hyperpermeability. In our patients treated with PDT (Group 5), 
choroidal thickness was significantly less, not only in the macular area, where the PDT 
had been previously performed, but also beyond the vascular arcade. The choroid in 
eyes that had developed CNV associated with angioid streaks was significantly thinner 
than was that of normal eyes. 
     Anti-VEGF treatments for CNV may also be involved in the thinner choroid in 
Groups 4 and 5. In a computerized search of PubMed, however, we could find no 
reference to a reduction of choroidal thickness due to anti-VEGF treatment. Recently, 
Koizumi and associates reported that in eyes with exudative AMD treated with 
ranibizumab, the mean subfoveal choroidal thickness decreased from 244 µm at the 
baseline to 226 µm at 3 months, 229 µm at 6 months, and 226 µm at 12 months (P < .01) 
(The 2011 Annual Meeting of American Academy of Ophthalmology, Orlando, FL, 
October 22-25, 2011). Although the authors found a statistically significant decrease in 
the foveal choroidal thickness, the mean reduction was only 18 µm. Based on this 
evidence, the effect of either PDT or anti-VEGF treatments on the choroidal thickness in 
our patients would be limited. Previous treatments for CNV do not explain sufficiently the 
decrease in macular choroidal thickness in eyes with CNV secondary to angioid streaks. 
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thickness not only in normal controls but in eyes with angioid streaks. In our subjects, the 
choroid in the nasal quadrant was thinner than in other quadrants; this thinning was most 
evident in the outer nasal sector. The reason for nasal choroidal thinning is unknown, but 
it may be related to the vascular bed distribution of the choroid and the choroidal 
watershed zone, which is frequently observed between the macula and optic disc.46 In 
eyes with angioid streaks, secondary CNV occurs usually adjacent to angioid streaks, 
sometimes in the peripapillary region.3, 4 Angioid streaks per se may be essential to the 
development of CNV. In addition, this thinning of nasal choroid might be related to the 
frequent occurrence of CNV secondary to angioid streaks at this site. However, while 
eyes with high myopia often show an extremely thin choroid, especially in the nasal 
quadrant of the macula, myopic CNV is seen usually around the fovea, rarely in the 
peripapillary area. In addition, all such eyes with a thin choroid do not show myopic CNV.  
Recently, choroidal thinning has been reported in eyes with exudative AMD,11 but so far, 
the clinical significance of choroidal thinning in the development of CNV has been 
insufficiently elucidated.47 
     One of the major limitations of the current study is the small sample size in each 
study group. Unexpectedly, the macular choroidal thickness in Group 3 was slightly 
thinner than that in Groups 4 and 5, although the difference was not statistically 
significant (P = .956 and P = .903). This difference could be explained by the variability of 
the macular choroidal thickness in eligible eyes, because the sample size of Group 3 was 
only 7. Due to this limitation, we could not precisely estimate the effect of previous 
treatments for CNV on the choroidal thickness. Another limitation of the current study is 
that the line of RPE and the chorioscleral border were determined manually. The raster 
scan protocol with over 60,000 measurement points would have minimized any error in 
measurement made by the observers, so software to determine these lines automatically 
is essential to further standardize this technique. 
     In spite of these limitations, our study did show that swept source OCT at 1 µm 
allows us to comprehensively evaluate the macular choroid in eyes with angioid streaks.  
The choroid in eyes without CNV secondary to angioid streaks was as thick as was that 
in normal controls, although the choroid was significantly thinner in eyes with angioid 
streaks that had developed CNV. In addition, the current study confirmed the asymmetric 
nature of the choroid in the macular area in eyes with angioid streaks. However, as this 
was a cross-sectional study, various interpretations of our findings are possible and it is 
difficult to determine whether choroidal thinning is a cause or a consequence of the 
development of CNV. Additional longitudinal prospective studies are needed to elucidate 
the role played by the choroid in the development of CNV in eyes with angioid streaks 
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Figure Captions 
 
Figure 1. Images of a healthy subject obtained with swept source optical coherence 
tomography (OCT) at 1,050 nm. (Left) A multi-averaged horizontal OCT image of 12 mm 
in length was obtained by averaging 50 images, which consisted of 1,024 A scans. Fine 
structure from the inner limiting membrane to the chorioscleral border is seen clearly 
beyond the vascular arcade. Regional changes in choroidal thickness are seen. (Middle 
and right) In a raster scan protocol, 128 consecutive images, consisting of 512 A-scans, 
were obtained. To reduce speckle noise, each image was enhanced by weighted moving 
average of three consecutive original images. (Middle) Single OCT image acquired with a 
raster scan protocol without weighted moving average. (Right) Single OCT image 
acquired with a raster scan protocol with weighted moving average. 
 
Figure 2. Multi-averaged horizontal section through the fovea obtained by swept source 
optical coherence tomography (left) and fundus photograph (right) in a healthy eye and in 
eyes with angioid streaks. (Top) A healthy eye (Group 1). Choroidal structures and the 
chorioscleral border are clearly seen. The choroid seems to be thin around the optic disc.  
(2nd row) An eye with angioid streaks without choroidal neovascularization (CNV) (Group 
2). The choroidal thickness is well preserved. (3rd row) An eye with CNV secondary to 
angioid streaks that had no history of treatments (Group 3). Choroidal thickness is 
substantially reduced in the entire macular area. (4th row) An eye with CNV secondary to 
angioid streaks that had previously received only anti-vascular endothelial growth factor 
treatments with no history of photodynamic therapy (PDT) (Group 4). Choroidal thickness 
is substantially reduced in the entire macular area. Regional thickening of the choroid is 
seen on the temporal side (arrow). (Bottom) An eye with CNV secondary to angioid 
streaks that was treated previously with PDT (Group 5). Choroidal thickness is reduced 
not only in the PDT-treated macular area but also beyond the vascular arcade. 
 
Figure 3. Choroidal thickness map of an eye with angioid streaks that had no choroidal 
neovascularization (group 2). (Top left) Fundus photograph of the right eye of a 
68-year-old man; visual acuity was 20/20. (Top right) Fluorescein angiogram shows only 
a window defect. (Middle) A multi-averaged horizontal image obtained with swept source 
optical coherence tomography clearly shows choroidal structures and the chorioscleral 
border. The choroid appears to have a physiologic thickness. (Bottom left) Choroidal 
thickness map of 6 × 6-mm2 of the macular area. Choroid in the nasal quadrant is thinner 
than is that of other quadrants. In addition, there is regional thickening in the outer 
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grid to the map, mean choroidal thickness was obtained for each sector. 
 
Figure 4. Choroidal thickness map of an eye with choroidal neovascularization (CNV) 
associated with angioid streaks. (Top left) Fundus photograph of the left eye of an 
80-year-old woman; visual acuity was 20/30. This eye was previously treated with one 
intravitreal injection of bevacizumab and 3 injections of ranibizumab (Group 4). (Top 
right) Fluorescein angiogram shows occult choroidal neovascularization. (Middle) A 
multi-averaged horizontal image obtained with swept source optical coherence 
tomography shows the thin choroid with type 1 choroidal neovascularization. (Bottom left) 
Choroidal thickness map of a 6 × 6-mm2 of the macular area. Choroidal thickness is 
reduced in the entire macular area. (Bottom right) By applying the ETDRS grid to the map, 
mean choroidal thickness was obtained for each area. 
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TABLE 1.  Characteristics of Eyes and Mean Choroidal Thickness and Volume Obtained by Swept Source Optical Coherence Tomography 










AS with CNV 
and no history 
of treatment 
AS with CNV 




AS with CNV 






Number of eyes 20 6 7 11 15  
Gender (male/female)  10/10 4/2 4/3 8/3 8/7  
Age (years) 67.4 ± 13.2 66.0 ± 6.8 65.1 ± 7.1 65.6 ± 7.8 66.7 ± 9.9  .960 
Axial length (mm) 23.5 ± 1.3 23.3 ± 1.0 23.6 ± 1.1 23.9 ± 1.5 23.4 ± 1.8  .949 
Refractive error (diopters) -0.51 ± 2.96 0.01 ± 1.02 0.11 ± 1.93 -1.38 ± 2.50 -2.20 ± 1.90  .134 
Visual acuity (logMAR) 0.01 ± 0.21 -0.14 ± 0.05 1.02 ± 0.32
*
 0.45 ± 0.61
*
 0.80 ± 0.45
*
 < .001 
Foveal retinal thickness (μm) 204.4 ± 35.5 194.0 ± 12.6 260.3 ± 119.5 209.9 ± 97.8 154.4 ± 64.3  .027 
Foveal choroidal thickness (μm) 254.8 ± 76.0 244.7 ± 51.0 142.0 ± 67.9
*
 144.0 ± 79.8
*
 124.8 ± 54.2
*
 < .001 
Mean choroidal thickness within a circle of 1.0-mm diameter (μm) 238.7 ± 75.0 239.0 ± 45.4 117.4 ± 55.9
*
 144.1 ± 69.8
*
 130.5 ± 52.8
*
 < .001 
Mean choroidal thickness within a circle of 3.0-mm diameter (μm) 233.0 ± 72.4 232.7 ± 49.7 116.5 ± 52.4
*
 139.0 ± 68.9
*
 137.7 ± 57.6
*
 < .001 
Mean choroidal thickness within a circle of 6.0-mm diameter (μm) 218.8 ± 69.2 218.9 ± 46.8 119.7 ± 49.2
*
 140.1 ± 64.9
†
 144.0 ± 52.6
†
 < .001 
Choroidal volume within a circle of 1.0-mm diameter (mm
3
) 0.187 ± 0.059 0.188 ± 0.036 0.092 ± 0.044
*
 0.113 ± 0.056
*
 0.102 ± 0.041
*
 < .001 
Choroidal volume within a circle of 3.0-mm diameter (mm
3
) 1.646 ± 0.512 1.644 ± 0.351 0.823 ± 0.370
*
 0.982 ± 0.487
*
 0.973 ± 0.407
*
 < .001 
Choroidal volume within a circle of 6.0-mm diameter (mm
3
) 6.183 ± 1.957 6.185 ± 1.323 3.381 ± 1.389
*
 3.959 ± 1.853
†
 4.070 ± 1.487
†
 < .001 
CNV (active/inactive) - - 4/3 5/6 1/14  
Treatment       
Number of anti-VEGF treatments 0 0 0 3.4 ± 2.1 3.1 ± 3.9  
Number of PDT treatments  0 0 0 0 2.9 ± 1.9  
AS = angioid streaks; CNV = choroidal neovascularization; PDT = photodynamic therapy; logMAR = logarithm of minimal angle of resolution; VEGF = vascular 
endothelial growth factor. 
*
P < .01, 
†
P < .05, compared with Group 1. 
 
Table 1




TABLE 2.  Choroidal Volume in Each Sector of ETDRS Grid Obtained with Swept Source Optical Coherence Tomography 
 
 Mean choroidal volume (mm3) 
 Group 1 Group 2 Group 3 Group 4 Group 5 
 






AS without CNV 
 
AS with CNV and no 
history of treatments 
AS with CNV and a 
history of only 
anti-VEGF treatments  
AS with CNV and a 
history of 
photodynamic therapy 
  Central area (P value*) 0.187 ± 0.059 0.188 ± 0.036 (1.000) 0.092 ± 0.043 (.001) 0.113 ± 0.056 (.002) 0.102 ± 0.041 (< .001) 
  Inner superior (P value*) 0.375 ± 0.114 0.402 ± 0.081 (.947) 0.186 ± 0.080 (.001) 0.232 ± 0.119 (.005) 0.229 ± 0.098 (.001) 
  Inner nasal (P value*) 0.354 ± 0.118 0.331 ± 0.084 (.990) 0.150 ± 0.615 (< .001) 0.203 ± 0.117 (.004) 0.164 ± 0.080 (< .001) 
  Inner inferior (P value*) 0.368 ± 0.113 0.352 ± 0.097 (.989) 0.182 ± 0.104 (.003) 0.207 ± 0.108 (.002) 0.228 ± 0.113 (.003) 
  Inner temporal (P value*) 0.369 ± 0.119 0.371 ± 0.073 (1.000) 0.212 ± 0.092 (.007) 0.226 ± 0.097 (.003) 0.249 ± 0.090 (.006) 
  Outer superior (P value*) 1.301 ± 0.379 1.361 ± 0.322 (.984) 0.753 ± 0.296 (.007) 0.887 ± 0.422 (.018) 0.873 ± 0.289 (.006) 
  Outer nasal (P value*) 0.939 ± 0.375 0.826 ± 0.218 (.878) 0.384 ± 0.192 (.002) 0.554 ± 0.384 (.014) 0.473 ± 0.220 (.001) 
  Outer inferior (P value*) 1.111 ± 0.394 1.173 ± 0.414 (.983) 0.659 ± 0.300 (.046) 0.713 ± 0.324 (.029) 0.805 ± 0.347 (.085) 
  Outer temporal (P value*) 1.185 ± 0.378 1.197 ± 0.231 (1.000) 0.770 ± 0.286 (.033) 0.806 ± 0.278 (.021) 0.946 ± 0.280 (.139) 
AS = Angioid streaks; CNV = choroidal neovascularization; VEGF = vascular endothelial growth factor; ETDRS = Early Treatment Diabetic Retinopathy 
Study.  
Mean choroidal volumes in each area were compared using one-way analysis of variance with Tukey’s post-hoc analysis.  
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TABLE 3.  Mean Choroidal Thickness in Each Sector of the ETDRS Grid Obtained with Swept Source Optical Coherence Tomography 
  Mean choroidal thickness of inner ring sectors (µm) 
  Inner superior Inner nasal Inner inferior Inner temporal  
Group 1 Normal eyes  
   (P value*) 
235.5 ± 75.4  
(.006) 
220.4 ± 75.0 234.4 ± 72.2  
(.058) 
235.5 ± 75.4 
(.043) 
Group 2 AS without CNV  
   (P value*) 
256.2 ± 51.6  
(.012) 
210.9 ± 53.6 224.0 ± 61.9  
(.724) 
236.5 ± 46.6  
(.217) 
Group 3 AS with CNV and no history of 
treatments (P value*) 
118.4 ± 50.9  
(.119) 
95.7 ± 39.2  
 
116.0 ± 66.4  
(.186) 
135.3 ± 58.5  
(.003) 
Group 4 AS with CNV and a history of only 
anti-VEGF treatments  (P value*) 
148.1 ± 75.9  
(.067) 
129.4 ± 74.9 132.1 ± 69.0  
(.983) 
144.0 ± 62.3  
(.202) 
Group 5 AS with CNV and a history of 
photodynamic therapy (P value*) 
145.7 ± 62.5  
(< .001) 
104.9 ± 51.2 
 
145.1 ± 72.2  
(< .001) 
158.7 ± 57.6  
(< .001) 
   
Mean choroidal thickness of outer ring sectors (µm) 
  Outer superior Outer nasal Outer inferior Outer temporal  
Group 1 Normal eyes  
   (P value*) 
245.6 ± 71.6  
(.001) 
177.2 ± 70.9 209.6 ± 74.5  
(< .001) 
223.6 ± 73.1  
(< .001) 
Group 2 AS without CNV  
   (P value*) 
256.9 ± 60.8  
(.001) 
155.9 ± 41.1 221.4 ± 75.0  
(.031) 
222.8 ± 40.2  
(.027) 
Group 3 AS with CNV and no history of 
treatments (P value*) 
142.1 ± 55.9  
(< .001) 
72.5 ± 36.3  
 
124.4 ± 56.6  
(< .001) 
145.3 ± 54.0  
(< .001) 
Group 4 AS with CNV and a history of only 
anti-VEGF treatments (P value*) 
167.5 ± 79.7  
(< .001) 
104.6 ± 72.6 134.6 ± 61.2  
(.022) 
155.1 ± 51.5  
(< .001) 
Group 5 AS with CNV and a history of 
photodynamic therapy (P value*) 
164.9 ± 54.5  
(< .001) 
89.4 ± 41.6 152.0 ± 65.2  
(< .001) 
178.3 ± 53.0  
(< .001) 
AS = angioid streaks; CNV = choroidal neovascularization; VEGF = vascular endothelial growth factor; ETDRS = Early Treatment Diabetic 
Retinopathy Study.  
Mean choroidal thickness in each sector was compared using two-way analysis of variance with Tukey’s post-hoc analysis.  
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Table of Contents Statement 
Using swept source-optical coherence tomography in the 1050 nm wavelength range, 
choroidal thickness of the macula area were examined in eyes with angioid streaks 
secondary to pseudoxanthoma elasticum. The choroid in eyes with angioid streaks 
without choroidal neovascularization was as thick as that in normal controls, but was 
significantly thinner in eyes with angioid streaks that had developed choroidal 
neovascularization. The choroid of the nasal quadrant was significantly thinner 
compared to that in other quadrants. 
*Table of Contents Statement (Original Articles only)
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Supplemental Figure Legends  
 
Supplemental Video 1. A series of images acquired across the macular area of a 
healthy eye. Images were obtained with swept source optical coherence tomography 
using a raster scan protocol of 512 (horizontal) x 128 (vertical) A-scans. To reduce 
speckle noise, each image was enhanced by weighted moving average of three 
consecutive original images. 
 
Supplemental Video 2. A series of images acquired across the macular area; these 
images show choroidal neovascularization secondary to angioid streaks. Images were 
obtained with swept source optical coherence tomography using a raster scan protocol of 
512 (horizontal) x 128 (vertical) A-scans. To reduce speckle noise, each image was 
enhanced by weighted moving average of three consecutive original images. The 
examined eye was treated six times with an intravitreal injection of ranibizumab. 
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